Cencora (NYSE: COR) Exceeds Earnings and Revenue Estimates
Key points
- Cencora's earnings per share of $4.66 surpassed the $4.58 estimate.
- Revenue reached $88.35 billion, exceeding the $87.95 billion estimate.
- The company reported strong revenue growth and provided key valuation metrics, including a trailing price-to-earnings ratio of 18.9.
Cencora (NYSE: COR) reported earnings before the market opened on November 4, 2026. Cencora distributes medicines and provides services to pharmacies, hospitals, and drug makers. Its earnings per share were $4.66, above the $4.58 estimate, while revenue was $88.35 billion, above the $87.95 billion estimate.
Revenue shows how much a company brings in before expenses. Cencora’s reported fiscal fourth-quarter revenue was $88.4 billion, up 5.5% from a year earlier, as highlighted by Business Wire. The $88.4 billion reported figure is rounded, while the $88.35 billion figure provides more detail. Full-year revenue rose 5.0% to $337.4 billion.
Cencora also reported GAAP diluted earnings per share of $2.71 for the quarter, compared with a loss of $1.75 per share a year earlier. GAAP earnings follow standard accounting rules. The company’s trailing price-to-earnings ratio is 18.9, meaning its share price is 18.9 times its earnings over the past 12 months.
Other measures give a broader view of Cencora’s valuation and finances. Its price-to-sales ratio is 0.19, and its enterprise-value-to-sales ratio is 0.21; enterprise value includes debt as well as the value of its shares. Its debt-to-equity ratio is 3.06, while its current ratio of 0.94 compares short-term assets with short-term liabilities.
Read the rest, free
Pop in your email to read every article in full and search any company. It takes five seconds.
You'll get Gro's newsletter too. Leave any time in one click.
